Home / Research Library / Compound Profiles
BPC-157 is a synthetic linear peptide of 15 amino acids, GEPPPGKPADDAGLV.1 It was first described in 1993 by researchers at the University of Zagreb as a partial sequence of a larger protein they reported in gastric juice, and the material used in laboratories is made by solid-phase peptide synthesis rather than extracted. In Australia it is listed in Schedule 4 and in Appendix D, clause 5, of the Poisons Standard.2
This profile describes the compound as a laboratory chemical: identity, structure, analytical checks, handling and regulation. Titan Peptides supplies it for laboratory and research use only; it is not for human consumption.
The 1993 description named a gastric juice protein of about 40,000 Da, BPC, and a 15-amino-acid fragment of it, BPC 157. The fragment is the compound now studied and supplied as BPC-157, and it is made synthetically. Several other names in the literature refer to the same peptide: the development codes PL 14736, PLD-116 and PL-10, and bepecin.1
| Property | Value |
|---|---|
| Class | Synthetic linear peptide (pentadecapeptide, 15 residues) |
| Sequence (one-letter) | GEPPPGKPADDAGLV |
| Sequence (three-letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 (free peptide, PubChem) |
| Molar mass | 1419.5 g/mol (PubChem) |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Other names | PL 14736, PLD-116, PL-10, bepecin |
| Australian status | Schedule 4; Appendix D, clause 5 (Poisons Standard, June 2026) |
Peptides are often supplied as salts, and PubChem also records a trifluoroacetate form of BPC-157, so the formula and mass on a given batch's documentation can legitimately differ from the free-peptide values above.1
BPC-157 is a linear chain with a free amino group on the N-terminal glycine and a free carboxyl group on the C-terminal valine. It is proline-rich, with three consecutive prolines at positions 3 to 5 and another at position 8. It carries three acidic side chains (one glutamic acid and two aspartic acids) against one basic side chain (lysine), so by the counting rule in our reconstitution guide it behaves as an acidic peptide when a solvent is being chosen.
The sequence contains none of the cysteine, methionine or tryptophan residues most prone to oxidation, and none of the asparagine or glutamine residues most prone to deamidation. That makes it simpler to store than many peptides, though solutions are still short-lived.
The name on a vial does not define its contents; analytical data do. Identity is shown by a mass spectrum whose observed mass matches the expected value for the stated form, 1419.5 g/mol for the free peptide, and purity by an HPLC chromatogram. Because the powder also contains counter-ions such as trifluoroacetate and some water, net peptide content and purity are reported separately. Our guides to how HPLC and mass spectrometry test peptide identity and purity and how to read a certificate of analysis explain what those figures mean and what to check.
Keep the sealed vial dry, dark and frozen at −20 °C or colder, and colder still (−50 to −80 °C) for long-term storage. Let it reach room temperature in a desiccator before opening, so moisture does not condense on the hygroscopic powder. Split a reconstituted stock into single-use aliquots, freeze them, and discard a thawed aliquot rather than refreezing it. See our guide to storing lyophilised and reconstituted peptides.
In the Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, which commenced on 1 June 2026, BPC-157 is listed in Schedule 4 (prescription-only medicines) and in Appendix D, clause 5, the table of poisons that "must not be possessed by a person without authority".2 The instrument also states that scheduling is implemented through state and territory legislation, and that the labelling exemption for poisons packed and sold solely for laboratory use "does not extend to controls on supply".2
The TGA's safety advisory of 13 April 2026 names BPC-157 as an example of an unapproved peptide product and states that a "research use only" disclaimer does not make its supply lawful.3 Our guide are research peptides legal in Australia? works through the framework.
BPC-157 is a synthetic linear peptide of 15 amino acids with the sequence GEPPPGKPADDAGLV and a free-peptide molar mass of 1419.5 g/mol. It was first described in 1993 by researchers at the University of Zagreb as a partial sequence of a larger protein reported in gastric juice. Research material is made by solid-phase peptide synthesis.
The CAS number for BPC-157 is 137525-51-0, and its PubChem compound ID is 9941957. The same peptide appears in the literature under the development codes PL 14736, PLD-116 and PL-10, and as bepecin, so a literature search should include every name.
Because 1419.5 g/mol is the free-peptide value. Peptides are often supplied as salts, and PubChem also records a trifluoroacetate form of BPC-157, which has a different formula and mass. Documentation should say which form it describes, and the observed peptide mass is what confirms identity.
In the June 2026 Poisons Standard, BPC-157 is listed in Schedule 4 and in Appendix D, clause 5, which covers poisons that must not be possessed without authority. The TGA names it as an unapproved peptide product and says a research-use-only label does not make supply lawful. Scheduling is implemented through state and territory legislation.
A chemical profile of TB-500, the N-acetylated LKKTETQ fragment of thymosin beta-4: identifiers, how the fragment and the full protein differ, where descriptions disagree, and how identity is checked.
What the TGA, the June 2026 Poisons Standard, the Therapeutic Goods Act and customs law actually say about peptides, "research use only" labels, import controls and advertising in Australia.
How reverse-phase HPLC and mass spectrometry are used to test peptide purity and identity, how to read a chromatogram and a mass spectrum, and what each method cannot tell you.
